Furthermore, while assessing treatment responses to doxorubicin in a mouse model of TNBC, we discovered that although the tumor response to treatment was similar in TLR9 siRNA and control siRNA TNBC groups, mice bearing TLR9 siRNA tumors lost significantly less weight than similarly treated mice with control siRNA tumors. The gene discussed is TLR9; the disease is neoplasm.